Cerebral palsy (CP) is a neurological disorder caused by abnormal development or damage to the motor control centers of the brain. It is the most common physical disability in children and can have a wide range of effects, such as muscle stiffness, lack of coordination, or difficulties with self-care and mobility. CP can be caused by a variety of factors, including congenital conditions, prenatal infections, perinatal injuries, and other environmental factors. The most common symptom of CP is a lack of coordination, which can manifest as difficulty walking, picking up objects, or speaking. Other motor impairments, such as difficulty with fine motor skills, can also be associated with CP. Cognitive and behavioral impairments, such as learning disabilities or attentional problems, can also be present. Speech impairments may also occur in children with CP, including mild articulation issues or more extreme issues like difficulty understanding language. CP can also lead to vision and hearing impairments, as well as issues with growth and development. Affected individuals may also experience various psychosocial problems, such as depression, anxiety, and other emotional issues. Seizures and other medical problems, such as digestive issues or urinary incontinence, may also be present. Early diagnosis and management of CP is important to minimize the effects of the condition and maximize physical and intellectual potential. This may include physical therapy, orthotic equipment, medications, and assistive technology. Depending on the severity of the symptoms, surgery may also be an option. As a chronic condition, the long-term effects of CP can vary. Most people with CP are able to live full and productive lives with appropriate support, while others may require more intensive care. It is important to note that CP is a complex condition and its effects can vary significantly from person to person.
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States